OrthoPediatrics Corp.
KIDS Healthcare Medical Devices
OrthoPediatrics Corp.’s revenue for fiscal 2025 (year ended December 2025) was $236.3 million, up 15.4% from fiscal 2024. In the quarter to June 2026, revenue grew 15.4%, EPS was flat, free cash flow grew 77.6% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow KIDS
OrthoPediatrics Corp. (KIDS) EV/Sales
As of 16 October 2026, OrthoPediatrics Corp. (KIDS) trades at a EV/Sales of 2.3×. Over the past ten years it has ranged from 0.9× (March 2018) to 16.0× (June 2021); the current reading is higher than 17% of that period. That is in line with the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.9× | (27.23%) |
| FY2024 | 2.6× | (42.35%) |
| FY2023 | 4.5× | (23.77%) |
| FY2022 | 6.0× | (46.81%) |
| FY2021 | 11.2× | 20.63% |
| FY2020 | 9.3× | 5.16% |
| FY2019 | 8.8× | 27.55% |
| FY2018 | 6.9× | 350.65% |
| FY2017 | 1.5× | 14.04% |
| FY2016 | 1.3× | 0.00% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.0× | 16.17% |
| Mar 2026 | 1.7× | (8.99%) |
| Dec 2025 | 1.9× | (8.44%) |
| Sep 2025 | 2.1× | (12.96%) |
| 35 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TCMD Tactile Systems Technology, Inc. compare | 1.3× |
| CTKB Cytek Biosciences, Inc. compare | 2.0× |
| KIDS OrthoPediatrics Corp. | 2.3× |
| BWAY Brainsway Ltd. Sponsored ADR compare | 2.6× |
| DCTH Delcath Systems, Inc. compare | 4.3× |
| SGHT Sight Sciences, Inc. compare | 4.9× |
| MASS 908 Devices Inc. compare | 5.6× |
| PACB Pacific Biosciences of California, Inc. compare | 5.9× |
| SSII SS Innovations International, Inc. compare | 9.6× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)